The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
This study will evaluate the potential therapeutic benefit of VentaProst in treating patients
with COVID-19 at risk for respiratory and/ or cardiac/circulatory failure. This is a
double-blind, placebo controlled study of VentaProst in 10 confirmed COVID-19 patients
compared to 10- COVID-19 placebo patients to assess the efficacy and safety of VentaProst
given over 10 days at varying doses.
Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
Other Name: inhaled Flolan
Inclusion Criteria:
- Confirmed COVID-19 positive by RT-PCR test
- Patients who require invasive mechanical ventilation.
- Consent or professional consent obtained
Exclusion Criteria:
- Patients on ECMO support.
- Patients receiving another inhalation research medication or inhaled nitric oxide.
- Not expected to survive for 48 hours.
- Allergy to Epoprostenol and its diluent
Ohio State University
Columbus, Ohio, United States
Veronica Franco, MD, Principal Investigator
Ohio State University